首页> 外文期刊>American Journal of Hypertension >Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes
【24h】

Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes

机译:奥美沙坦/氨氯地平与培哚普利/氨氯地平对2型糖尿病患者服药后外周和中枢血压参数功效的比较研究

获取原文
获取原文并翻译 | 示例
           

摘要

Central aortic blood pressure (CBP) and CBP-derived parameters are independent predictors of cardiovascular risk. Angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors plus calcium channel blockers are the recommended first-line treatments in hypertensive diabetic patients; however, the effect in reducing CBP when a dose is skipped has not been established yet. The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine (OLM/AML) provides equal efficacy and safety as the perindopril/AML (PER/AML) combination in reducing CBP, augmentation index (AIx), and pulse wave velocity (PWV) when a drug dose is missed.
机译:主动脉中央血压(CBP)和CBP衍生参数是心血管风险的独立预测因子。在高血压糖尿病患者中,推荐的一线治疗是血管紧张素II受体阻滞剂(ARB)或血管紧张素转化酶抑制剂加钙通道阻滞剂。然而,尚未确定在跳过剂量时降低CBP的效果。目的是确定固定剂量的奥美沙坦/氨氯地平(OLM / AML)组合在降低CBP,增强指数(AIx)和脉搏波速度方面是否与培哚普利/ AML(PER / AML)组合具有同等效力和安全性(PWV)错过药物剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号